<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Low uptake of monoclonal antibodies (MAbs) in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> lesions is a significant problem in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy </plain></SENT>
<SENT sid="1" pm="."><plain>Recent studies have shown that antibody uptake in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> is controlled in large part by the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> blood flow and the vascular permeability of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> endothelium </plain></SENT>
<SENT sid="2" pm="."><plain>We have hypothesized that these physiological properties of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> vessels may be altered by pretreatment with vasoactive drugs or <z:chebi fb="7" ids="16670">peptides</z:chebi> linked to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific MAbs </plain></SENT>
<SENT sid="3" pm="."><plain>To test this hypothesis, two MAbs, Lym-1 directed against human malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and B72.3 reactive with the TAG-72 antigen expressed in <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>, were chemically conjugated with human recombinant interleukin 2 (IL-2) </plain></SENT>
<SENT sid="4" pm="."><plain>IL-2 has been used in humans to activate lymphokine-activated killer cells for the treatment of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> but is also known to produce a generalized vascular permeability by an unknown mechanism when used systemically </plain></SENT>
<SENT sid="5" pm="."><plain>Chemical conjugation of IL-2 to MAbs appears to destroy its cytokine function as shown by T-cell proliferation studies in vitro </plain></SENT>
<SENT sid="6" pm="."><plain>Despite this finding, MAb/IL-2 immunoconjugates retain their ability to produce an enhanced vascular permeability when injected i.v. into <z:mp ids='MP_0003815'>nude</z:mp> mice bearing relevant <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> models only </plain></SENT>
<SENT sid="7" pm="."><plain>Biodistribution studies using 125I-labeled tracer Lym-1 have demonstrated that the Lym-1/IL-2 immunoconjugate can increase antibody uptake in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> by a factor of 4 in a time (2.5-h pretreatment)- and dose (30 micrograms/mouse)-dependent manner </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast, treatment of mice with free IL-2 and antibody showed this effect in <z:hpo ids='HP_0000001'>all</z:hpo> organs of the mouse including the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Bidirectional crossover imaging studies in individual <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-bearing <z:mp ids='MP_0003815'>nude</z:mp> mice showed improved uptake and decreased blood pool when the MAb/IL-2 immunoconjugates were used compared to controls </plain></SENT>
<SENT sid="10" pm="."><plain>Finally, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> blood flow and vascular permeability studies demonstrate that the physiological effect of the MAb/IL-2 is due to a reversible and specific vascular leakage at the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> site </plain></SENT>
<SENT sid="11" pm="."><plain>These studies indicate that pretreatment with this novel immunoconjugate may enhance the diagnostic and therapeutic potential of MAbs, drugs, and other macromolecules for the treatment of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>